Indexing metadata

Effectiveness of Tixagevimab/cilgavimab for SARS-CoV-2 Pre‑exposure Prophylaxis in Hemodialysis Patients: A Retrospective Cohort Study from a Tertiary Hospital in Thailand

 
Dublin Core PKP Metadata Items Metadata for this Document
 
1. Title Title of document Effectiveness of Tixagevimab/cilgavimab for SARS-CoV-2 Pre‑exposure Prophylaxis in Hemodialysis Patients: A Retrospective Cohort Study from a Tertiary Hospital in Thailand
 
2. Creator Author's name, affiliation, country Phangard Neamrat; Trang Hospital, Mueang, Trang 92000,; Thailand
 
2. Creator Author's name, affiliation, country Chawalin Inthong; Innovation Unit for Consumer Protection in Healthcare Products, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla 90110,; Thailand
 
3. Subject Discipline(s)
 
3. Subject Keyword(s) COVID-19; end-stage kidney disease; hemodialysis; pre‑exposure prophylaxis; Tixagevimab/cilgavimab
 
4. Description Abstract

Objectives: To evaluate the effectiveness and safety of Tixagevimab/cilgavimab as pre-exposure prophylaxis against coronavirus disease 2019 (COVID-19) in patients with end-stage kidney disease (ESKD) undergoing hemodialysis during the Omicron surge.
Material and Methods: This retrospective cohort study was conducted at Trang Hospital, Thailand, from September 2022 to March 2024. Adult ESKD patients receiving maintenance hemodialysis were included. Patients who received Tixagevimab/cilgavimab were compared with those who did not. The primary outcomes included asymptomatic and symptomatic COVID-19 infection, COVID-19-related hospitalization, and mortality over 18 months. Kaplan-Meier curves and Cox proportional hazards models were used to assess outcomes. The secondary outcome was adverse events after administration.
Results: Among 207 patients (40 intervention, 167 controls), incidence rates of symptomatic infection (0.261 vs. 1.432 per 1,000 person-days) and COVID-19-related hospitalization (0.047 vs. 0.236 per 1,000 person-days) were lower in the intervention group. No COVID–19–related deaths occurred. Tixagevimab/cilgavimab significantly reduced the risk of symptomatic infection (adjusted hazard ratio 0.22; 95% CI, 0.087–0.545). Adverse events were infrequent and mild.
Conclusion: Tixagevimab/cilgavimab was associated with a significant reduction in symptomatic COVID-19 infection among hemodialysis patients during the Omicron wave. Although hospitalization rates were lower in the intervention group, the difference was not statistically significant. The treatment was well tolerated and may provide preventive benefits for high-risk ESKD populations.
 
5. Publisher Organizing agency, location Faculty of Medicine, Prince of Songkla University
 
6. Contributor Sponsor(s)
 
7. Date (YYYY-MM-DD) 2026-03-18
 
8. Type Status & genre Peer-reviewed Article
 
8. Type Type
 
9. Format File format PDF
 
10. Identifier Uniform Resource Identifier https://www.jhsmr.org/index.php/jhsmr/article/view/1287
 
10. Identifier Digital Object Identifier (DOI) http://dx.doi.org/10.31584/jhsmr.20251287
 
11. Source Title; vol., no. (year) Journal of Health Science and Medical Research; Vol 44, No 3 (2026): May-Jun
 
12. Language English=en en
 
13. Relation Supp. Files
 
14. Coverage Geo-spatial location, chronological period, research sample (gender, age, etc.)
 
15. Rights Copyright and permissions Copyright (c) 2025 Journal of Health Science and Medical Research Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.